Numerous studies have shown that serum Chil3l1 can serve as a useful biomarker for the diagnosis and severity of CAD independent of common risk factors plus high-sensitivity C-reactive protein (hs-CRP) and N-terminal-pro-B natriuretic peptide (NT-proBNP), whereas treatment with certain drugs, such as statins, has no influence on the effectiveness of Chi3l1 as a superior prognostic biomarker in CAD patients [111,112,113]. This evidence concerns the gene CHI3L1 and coronary artery disorder.